Georgia lacks plan to distribute new COVID vaccines to most vulnerable
Millions of people are pinning hopes for a return to normal on a COVID-19 vaccine as cases and deaths continue to mount in Georgia and the U.S., but public health officials have work to do to make sure communities hit hardest by the virus have access to treatment.
Two potential vaccine candidates are showing promising results in preliminary tests. On Monday, Moderna Inc. announced its two-dose trial vaccine was 94.5% effective in a clinical study.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” said Moderna CEO Stéphane Bancel. “Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters.”
Another vaccine series from Pfizer Inc was found similarly effective last week. Both companies are asking the Food and Drug Administration to be able to begin shipping the vaccines under an emergency use plan.
Read more: https://georgiarecorder.com/2020/11/18/georgia-lacks-plan-to-distribute-new-covid-vaccines-to-most-vulnerable/
